These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9728999)

  • 1. Regimen lowers rate of coronary events in diabetes.
    Husten L
    Lancet; 1998 Aug; 352(9129):711. PubMed ID: 9728999
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 3. [The MULTISTRATEGY study].
    Danzi GB; Marzocchi A
    G Ital Cardiol (Rome); 2009 Jun; 10(6):353-7. PubMed ID: 19603605
    [No Abstract]   [Full Text] [Related]  

  • 4. The TARGET trial: hit or miss?
    Moliterno DJ; Topol EJ
    Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
    [No Abstract]   [Full Text] [Related]  

  • 5. [The FATA study].
    Merlini PA; Valgimigli M
    G Ital Cardiol (Rome); 2009 Jun; 10(6):358-63. PubMed ID: 19603606
    [No Abstract]   [Full Text] [Related]  

  • 6. [The AIDA STEMI study].
    Prati F; Limbruno U
    G Ital Cardiol (Rome); 2013 Oct; 14(10):631-5. PubMed ID: 24121885
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD40 ligand in acute coronary syndromes.
    Kritharides L; Lau GT; Freedman B
    N Engl J Med; 2003 Jun; 348(25):2575-7; author reply 2575-7. PubMed ID: 12815146
    [No Abstract]   [Full Text] [Related]  

  • 9. Soluble CD40 ligand in acute coronary syndromes.
    Heeschen C; Dimmeler S; Hamm CW; van den Brand MJ; Boersma E; Zeiher AM; Simoons ML;
    N Engl J Med; 2003 Mar; 348(12):1104-11. PubMed ID: 12646667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of unstable angina pectoris. Thrombocyte aggregation inhibition improves chances for survival].
    Z Kardiol; 1998 Aug; 87(8 Suppl Thrombozy):1-3. PubMed ID: 9789356
    [No Abstract]   [Full Text] [Related]  

  • 11. The Year in Cardiology 2012: coronary intervention.
    Redwood SR
    Eur Heart J; 2013 Feb; 34(5):338-44. PubMed ID: 23284091
    [No Abstract]   [Full Text] [Related]  

  • 12. Facilitated PCI: crossing the bridge with lessons learned.
    Mishra S; Bahl VK
    Indian Heart J; 2009; 61(5):410-2. PubMed ID: 20635753
    [No Abstract]   [Full Text] [Related]  

  • 13. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 15. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 16. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 18. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'.
    Montalescot G
    Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056
    [No Abstract]   [Full Text] [Related]  

  • 19. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.